GeoVax Labs, Inc. (GOVX)


-0.02 (-2.42%)
Symbol GOVX
Price $0.81
Beta 1.792
Volume Avg. 10.11M
Market Cap 10.164M
Shares () -
52 Week Range 0.55-7.5
1y Target Est -
DCF Unlevered GOVX DCF ->
DCF Levered GOVX LDCF ->
ROE -146.19% Strong Sell
ROA -115.31% Strong Sell
Operating Margin -
Debt / Equity 48.45% Neutral
P/E -
P/B 0.45 Neutral


Consensus EPS

Upgrades & Downgrades

Latest GOVX news

Mr. David Alan Dodd
NASDAQ Capital Market

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.